MedTrace Logo

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300482 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1445

Last updated 2009-06-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.

Conditions

Interventions

DRUG

ABT-335

135 mg, daily, 12 weeks

DRUG

Rosuvastatin Calcium

Daily, 12 weeks, see Arm Description for dosage information

DRUG

Placebo

Daily, 12 weeks, see Arm Description for information regarding placebo type

Sponsors & Collaborators

Principal Investigators

  • Maureen Kelly, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300482 on ClinicalTrials.gov